Stockreport

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates

Neurogene Inc.  (NGNE) 
PDF Remains on track to provide regulatory update on registrational trial plans with NGN-401 for Rett syndrome in the first half of 2025Continues to expect to share addition [Read more]